Drug Profile
Octreotide needle-free injectable - Glide/Endo
Alternative Names: Glide octreotide; GP-02; Octreotide SDILatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Glide Pharma
- Developer Endo International; Glide Pharma; Glide Technologies
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acromegaly
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for phase-I development in Acromegaly in United Kingdom (SC, Needle-free injection)
- 28 Jun 2016 Glide Technologies completes a phase I trial in Acromegaly in United Kingdom (SC)
- 19 May 2016 Phase-I clinical trials in Acromegaly in United Kingdom (SC)